Live Natco Pharma Share Price Chart

O 970

H 970

L 970

VOL 1494

Natco Pharma Performance

Days Range

Low: ₹970.00
High: ₹992.40
Previous Close ₹982.45
Open ₹970.00
Volume 1,04,697
Day’s Range ₹970.00 - ₹992.40
52W Range ₹551.00 - ₹1,108.35
Market Cap ₹17,591 Cr

Natco Pharma Fundamentals

ROCE (TTM) 24.54
P/E Ratio (TTM) 13.77
P/B Ratio 3.32
Industry P/E 36.29
Debt to Equity 0.05
ROE 21.3
EPS (TTM) 71.34
Dividend Yield 0.57
Book Value 295.55
Face Value 2

Natco Pharma Financials

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales897.91,140.51,031.4758.6
Expenses599.8656617534.7
Profit before tax324.4500439.6256.3
Operating Profit275.8420.3369212.7
Net Profit275.8420.3369212.7
EPS in Rs15.1123.2620.611.88

About Natco Pharma

History of Natco Pharma Limited

Incorporated in 1981, Natco Pharma Limited is involved in the manufacturing and sale of pharmaceutical products. 

The company was started in 1981 in Kothur, Mahaboobnagar district, Telangana. In 1986, they opened a parental manufacturing unit at Nagarjunasagar. In 1993, the company inaugurated a chemical division at Mekaguda. In 1995, Natco Trust was founded, and Natco merged three of the group companies with the parent company. In the same year, they went public and got listed on the Indian stock exchanges. In 1997, they opened the Natco Research Centre (NRC). 

In 2003, the company entered the Oncology division and launched its flagship brand, Veenat. In 2006, Natco Pharma Limited established a finished dosage unit at Dehradun. In the next year, i.e., in 2007, they launched their first Abbreviated New Drug Application (ANDA) in the USA. They also acquired Savemart Pharmacy in the USA. In 2009, the company established Natco Organics in Chennai, and in the same year, the company turnover touched $100 million. Between 2013 and 2014, the company established in Canada and Australia. 

In 2016, Natco Pharma Limited sold Savemart Pharmacy in the USA. In 2017, they entered the Diabetology and Cardiology divisions. In 2018, they launched Teriflunomide, the company’s first generic version of oral tablets for multiple sclerosis in India. In 2019, they launched the crop health science division. In 2020, the company’s Vishakapatnam Formulation unit was approved by the US FDA. In the same year, Natco Pharma supplied COVID-19 treatment tablets, Chloroquine Phosphate tablets in the USA. In 2021, the company launched other drugs for Covid treatment. In 2022, Natco Pharma’s crop health science division launched agro products in India. 

As of March 2023, Natco Pharma Limited has a presence in more than 50 countries and 465 scientists. They have 5 Finished Dosage Forms (FDF) manufacturing units, 2 Active Pharmaceutical Ingredients (API) manufacturing units, 2 R&D centres and 2 crop health sciences units. 

Business Segments of Natco Pharma Limited 

The two primary business segments of the company are as follows: 

  • Pharmaceuticals: In this segment, the company is involved in the development, manufacturing and marketing of FDF and APIs. 
  • Agrochemicals: In this segment, the company focuses on providing eco-friendly biopesticide products for farmers, thus contributing to sustainable farming.

As of March 31, 2023, a few of the subsidiaries of Natco Pharma Limited are as follows:

  • Natco Pharma Inc: This wholly-owned subsidiary of the company is involved in the retail sale of prescription drugs and non-prescription medicines. 
  • Natco Pharma Australia Pty Ltd: This wholly-owned subsidiary of the company was established for the sale and distribution of pharmaceutical products in Australia. 
  • Natco Pharma (Canada) Inc: This wholly-owned subsidiary of the company was established for the sale and distribution of pharmaceutical products in Canada. 

Key Personalities of Natco Pharma Limited

V.C. Nannapaneni, Managing Director

V.C. Nannapaneni is the Managing Director of Natco Pharma Limited. He has more than 40 years of experience in the pharmaceutical sector. In addition to handling general management responsibilities, he supervises the New Drug Discovery program within the company.

Parent Organisation Natco
Founded 1981
Managing Director G S Murthy
NSE Symbol NATCOPHARM

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Supriya Lifescience Ltd ₹2,931.99

363.1

0.50 (-0.14%)

359 - 366.7View Peer Comparison
Celestial Biolabs Ltd ₹4.56

1.75

0.00 (0.00)

1.75 - 1.8View Peer Comparison
JFL Life Sciences Ltd ₹43.99

40

0.00 (0.00)

40 - 42.5View Peer Comparison
Procter & Gamble Health Ltd ₹7,770.96

4704.5

17.25 (0.37%)

4666.5 - 4712.9View Peer Comparison
Veerhealth Care Ltd ₹44.48

26

0.00 (0.00)

26 - 26View Peer Comparison

What's Trending

Natco Pharma FAQs

What is the Share price of Natco Pharma (NATCOPHARM)?

Natco Pharma (NATCOPHARM) share price as of April 16, 2024, on NSE is Rs 989.55 (NSE) and Rs 991.20 (BSE) on BSE.

Can I buy Natco Pharma (NATCOPHARM) shares?

Yes, You can buy Natco Pharma (NATCOPHARM) shares by opening a Demat account with Angel One.

How do I buy Natco Pharma (NATCOPHARM) from Angel One?

Natco Pharma (NATCOPHARM) share can be brought through the following modes:
  1. Direct investment: You can buy Natco Pharma (NATCOPHARM) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Natco Pharma (NATCOPHARM) shares.

Is NATCO Pharma a Debt free Company?

Yes, NATCO Pharma is a virtually debt-free company.

What is the main business of NATCO Pharma?

The main business of NATCO Pharma is the production and distribution of pharmaceutical products, including generic drugs and active pharmaceutical ingredients (APIs). They also place an emphasis on pharmaceutical research and development.

Who are the promoters of NATCO Pharma?

VC Nannapaneni, Time Cap Pharma Labs Limited, Venkata Satya Swathi Kantamani, Natsoft Information Systems Pvt Ltd are the major promoters of NATCO Pharma.

What are the Subsidiaries that comes under NATCO Pharma?

NATCO Trust, NATCO Organics, and NATCO Biotech are all subsidiaries of NATCO Pharma. These subsidiaries focus on organic chemicals, biotechnology, and healthcare services, respectively.